Shi, Yuankai <br/><br/>
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.  [electronic resource] 

 -  EBioMedicine  Apr 2020 
 - 102731 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>2352-3964 
<br/><br/><label>Standard No.: </label>10.1016/j.ebiom.2020.102731  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Circulating Tumor DNA--genetics<br/>DNA-Binding Proteins--genetics<br/>Drug Resistance, Neoplasm<br/>F-Box Proteins--genetics<br/>Female<br/>Hodgkin Disease--blood<br/>Humans<br/>Immune Checkpoint Inhibitors--therapeutic use<br/>Jumonji Domain-Containing Histone Demethylases--genetics<br/>Male<br/>Middle Aged<br/>Mutation<br/>Receptors, Tumor Necrosis Factor, Member 14--genetics<br/>Transcription Factors--genetics<br/>beta 2-Microglobulin--genetics